Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Thermo Fisher Scientific was proud to partner with the Association for Molecular Pathology (AMP) for the 2022 Annual Meeting and Expo in Phoenix, AZ, Nov 1-5. The event provided us with a great opportunity to reconnect in-person with many of our colleagues and partners from around the world.
As the world leader in serving science, Thermo Fisher Scientific enables our partners to conduct genomic discoveries and help improve clinical outcomes through our innovative technologies, workflows and services across the genomic continuum.
A select number of our corporate workshop recordings and scientific posters are now available to view on demand.
Below, you can find additional information on all of the workshops and poster sessions presented by Thermo Fisher Scientific at AMP 2022.
Thursday, November 3
3:50—4:20 pm
Stage 2
ChromaCode leveraged their high definition PCR (HDPCR™) technology to expand multiplexing bandwidth on the Absolute Q dPCR platform. Together with the Absolute Q system's consistent and robust microfluidic array plate (MAP) technology, this will enable the creation of high information content and fast turnaround assays for clinical research applications. We highlight the power of HDPCR on dPCR with data from a prototype oncology assay that yields mutation status for 14 DNA variants and 15 RNA fusion variants relevant in NSCLC samples. We demonstrate over 95% concordance with an NGS reference standard in a cohort of contrived and clinical (FFPE and liquid biopsy) samples.
The COVID-19 pandemic underscored the importance of molecular diagnostics and compelled laboratories to quickly validate new methods and increase testing capacity. Aegis Sciences Corporation has performed over 13.8M COVID-19 tests and has a capacity over 100,000 tests/day, servicing a broad network of physicians, urgent care centers, nursing homes, public schools, departments of health, and retail pharmacies across the United States. As the virus moves towards an endemic state and testing demand decreases, Aegis leveraged the partnerships, technologies, and infrastructure developed during the COVID-19 surge for new diagnostic offerings and strategies to expand molecular testing and prepare for future public health needs.
Time: 9:00 AM
Room: 224A
Speakers:
Fernando Torres, Genomics Product Manager, Q2Solutions: Results of the Evaluation of Oncomine Precision Assay in CRO Setting
Jon Sherlock, Oncology Product Director, Thermo Fisher Scientific: Oncomine Comprehensive Assay Plus on Genexus System - CGP in 48 hours
NGS implementation barriers including turnaround time and level of automation are being addressed. Join our workshop to hear how the Ion Torrent Genexus System enables labs to offer fast results, excellent sample success, and a true end-to-end workflow with integrated bioinformatics. With a growing menu of assays, the Genexus System can generate results in as little as 24 hrs for a targeted panel, and less than 48 hrs for a comprehensive panel with complex biomarkers including a genomic instability metric.
Time: 9:00 AM
Room: 224B
MAKO Medical Laboratories, a national reference laboratory and leader in SARS-CoV-2 testing is now one of fewer than 100 laboratories across the country capable of performing surveillance testing for monkeypox research. Mako Medical has developed a workflow for monkeypox surveillance testing to support health state department in furthering the research of monkeypox viral epidemiology. The MAKO Medical team shares their journey of responding to the need for more surveillance testing capacity in the United States for monkeypox research. Gain insights from a question-and-answer discussion format of the team’s decision on their workflow, including sample types, automation, reagents, and throughput.
Time: 10:00 AM
Room: 224A
Speakers:
Cecilia Yeung, MD. Associate Professor Clinical Research Division, Fred Hutch Sophie Rozenzhak, PhD. Product Manger, Thermo Fisher Scientific
Next-generation sequencing (NGS) is becoming a critical component of molecular testing in both myeloid and lymphoproliferative neoplasms. During this workshop, hear from experts on the latest advances in the application of fast NGS for myeloid genomic profiling, myeloid measurable residual disease (MRD), and B-cell and T-cell sequencing applications for clonality assessment and detection of low-frequency residual clones. Talks will feature our latest NGS testing solutions, including the Ion Torrent Genexus System, which offers a fully complete end-to-end workflow capable of delivering results in just 1-2 days. See how these groundbreaking testing methods are helping to advance research in hemato-oncology care.
Time: 10:00 AM
Room: 224B
Molecular testing infrastructure is critical for laboratories to rapidly respond during public health emergencies. Partnerships with public and private sector entities to expand resources, innovation, and capabilities support these efforts and limit the spread of health risks within the community. The lessons learned from COVID-19 can be directly applied to the Monkeypox virus outbreak to improve preparedness, response, and community engagement for detection and prevention. Utilizing previously developed networks has dramatically reduced the response time to an emerging public health threat. Maintaining national laboratory capacity and infrastructure is a hedge against an increasingly interconnected world of transmissible pathogens.
Time: 11:00 AM
Room: 224A
From monitoring tumor biomarkers that inform treatment selection to tracking viral outbreaks using wastewater surveillance, dPCR enables clinical researchers and public health labs to quantitate nucleic acid targets reliably. The powerfully simple Absolute Q dPCR MAP technology enables less than 2% dead volume to help ensure rare target quantitation and detection are precise. Learn how a flexible workflow with 5-minute setup and 90-minute runs can expand the capabilities of your lab, and explore our latest innovations, including verified liquid biopsy assays, an optimized SARS-CoV-2 wastewater kit, and a custom assay design tool powered by more than 40 years of expertise.
Time: 11:00 AM
Room: 224B
Speakers:
Salvatore Priore, MD, PhD, Assistant Professor of Clinical Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania: Biomarker testing for NSCLC in 2022
Melina Marmarelis, MD, Medical Oncologist at the University of Pennsylvania: Case Studies: Current standard of care for treating patients with HER2-mutant mNSCLC
During this workshop, the speakers will review the latest biomarker developments in non-small cell lung cancer (NSCLC), including emerging biomarkers, such as HER2 (ERBB2) mutations.
The oncologist and pathologist speakers from the same institution will discuss bringing together their complementary practices to provide the best possible diagnostic and therapeutic approaches to each individual patient. They will address how implementing next generation sequencing technology in-house can enable rapid turnaround times to facilitate clinical decision making. They will share their best practices for implementing a collaborative molecular tumor board and strategies for working together towards individualized treatments for their patients.
Time: 12:00 PM
Room: 230
Complicated UTIs require rapid and accurate test results for pathogen identification and antibiotic susceptibility. Standard urine culture has significant shortcomings, including a long delay before results and negative or “mixed flora/contamination” results for clear cases of UTI. Guidance® UTI is a precision diagnostic providing the sensitivity of PCR plus Pooled Antibiotic Susceptibility (P-AST™) measuring antibiotic susceptibility against the pool of polymicrobial organisms. By providing rapid and actionable results to the clinician, Guidance® UTI is associated with improved patient outcomes, with a 67% reduction of inpatient admissions and an average $463 reduction per complicated UTI case in Medical Resource Utilization costs.
Time: 1:00 PM
Room: 224A
Speakers:
Donna Wolk, MHA, PhD, D(ABMM), Division Chief, Molecular and Microbial Diagnostics and Development, Geisinger Medical Laboratories
Jennifer Dien Bard, PhD, D(ABMM), FIDSA Professor of Pathology Keck School of Medicine of USC
The promise of unlocking new frontiers in microbiology using modern technologies like NGS has been at the forefront of discussion recently. With a significant increase in access to these technologies through pandemic response programs, we are now positioned to realize that promise through exploration and implementation of applications such as pathogen identification, tracking of AMR markers, and microbiome profiling. Limitations of cumbersome workflows, long turnaround times, and complex analyses have largely been removed, though there is still significant opportunity ahead of us in order to pivot many well-established culture-based approaches to newer molecular methods using NGS.
Time: 1:00 PM
Room: 224B
As leader in RT-PCR, Thermo Fisher Scientific committed to provide innovative, and flexible systems needed for laboratories to expand their IVD testing capabilities. For over 10 years, Thermo Fisher Scientific developed high-performance RT PCR (qPCR) instruments for clinical laboratories across the world. Our innovative IVDR compliant qPCR instruments showcase built-in smart features, user-friendly interfaces, integrated, intuitive, and modular software solutions along with user support and training. As a leader in RT-PCR, Thermo Fisher Scientific's molecular diagnostics solutions enable actionale results accurately and quickly to meet your laboratory needs.
Time: 2:00 PM
Room: 224A
Speakers:
Jeremy Stuart, PhD, MPH, Chief Science Officer, Precision Genetics
Fiona Hyland, MSc Director of R&D, Bioinformatics Thermo Fisher Scientific
Postoperative pain control remains a huge challenge for healthcare systems though there are currently no tools available to routinely select personalized medication. Multiple genes have been implicated in explaining some variation among postoperative response and studies indicate that single-gene pharmacogenetic analysis can improve postop outcomes. However, most professional guidelines only provide recommendations for single gene/drug interactions. Precision Genetics, in cooperation with MUSC Health System, is undertaking the PRospective Outcomes and Molecular Implementation Support Registry (PROMISRx) Study to better explain interpatient variability in response to perioperative treatment and lead to the creation of a tool for predicting postoperative outcomes.
Time: 2:00 PM
Room: 224B
Platform Presentations of Selected Infectious Diseases Abstracts: Balancing Act in the Face of Variants: Testing Strategies to Minimize Infections and Maximize In-Person Learning in Schools
Poster #ID014, date: 11/5/2022, 9:15am-10:15am PST
Oral Platform, date: 11/05/2022, 1:30pm-1:45pm PST
PCR-based Genotyping: Better, Faster and Cheaper than Whole Genome Sequencing for Known Viral Strain Identification
Poster # ID024, date: 11/04/2022, 9:15am-10:15am PST
Expanded PCR panel testing for Identification of Respiratory Pathogens and Coinfections in Influenza-like Illness
Poster # ID051, date: 11/05/2022, 9:15am-10:15am PST
Balancing Act in the Face of Variants: Testing Strategies
Poster # ID014, date: 11/04/2022, 9:15am-10:15am PST
Validation of Applied Biosystems HIV-1 Genotyping Kit with Integrase (Thermo Fisher Scientific) performed on the ABI 3500xL Genetic Analyzer platform
Poster # ID059, date: 11/05/2022, 9:15am-10:15am PST
Development of Monkeypox virus molecular control as reference material for molecular diagnostic tests
Poster # ID067, date: 11/05/2022
Development of a Multiplex RT-qPCR Assay for the Simultaneous Detection and Differentiation of Human Adenovirus, Metapneumovirus, Parainfluenza Virus and Rhinovirus/Enterovirus
Poster # ID057, date: 11/05/2022, 9:15am-10:15am PST
Development and Performance Evaluation of a Multiplex Real-Time PCR Panel for the Qualitative Detection and Differentiation of Enteric Bacterial Pathogens
Poster # ID011, date: 11/05/2022, 9:15am-10:15am PST
Precision Genotyping for EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Using a Multiplexed Digital PCR Test
Poster # ST07
Development of New Multianalyte NGS controls with microsatellite instability, tumor mutation burden and loss of heterozygosity variants
Poster # ST073, date: 11/05/2022
Development of AcroMetrix Multi-analyte cfTNA (cell free total nucleic acid) Human Plasma Controls
Poster # ST070, date: 11/05/2022
Multifaceted Research Application of Comprehensive Genomic Profiling for Detection of Cancer Variants, Gene Fusions, and Complex Oncology Endpoints
Poster # ST017, date: 11/05/2022, 9:15am - 10:15am PT
Comprehensive profiling of copy number changes to assess genomic instability
Poster # ST059, date: 11/05/2022, 9:15am - 10:15am PT
NYSDOH Initial Validation of the Oncomine™ Precision Assay for Use in Clinical Studies
Poster # ST021, date: 11/05/2022, 9:15am - 10:15am PT
Expanded International Scale (IS) Value Assignments to our BCR-ABL1 Panel and Development of Daily Controls Traceable to WHO International Standards
Poster # H031, date: 11/05/2022
Efficient Biorepository Development using Oncomine Precision Assay and the Genexus Integrated NGS Platform
Poster # I017, date: 11/05/2022, 9:15am - 10:15am PT
Automated Mutation Impact Analysis Tool for Real-Time Tracking of SARS-CoV-2 Variant Impact on COVID Diagnostic Assays
Poster # I013, date: 11/05/2022, 9:15am-10:15am PST
Labor Cost Comparison between the Thermo Fisher Scientific Genexus Integrated Sequencer and the Illumina MiSeq
Poster # G049, date: 11/05/2022, 9:15am - 10:15am PT
Precision Genotyping for EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Using Multiplexed Digital PCR on cell-free DNA
Poster # G052, date: 11/04/2022, 9:15am - 10:15am PT
Platform Presentations of Selected Infectious Diseases Abstracts: Balancing Act in the Face of Variants: Testing Strategies to Minimize Infections and Maximize In-Person Learning in Schools
Poster #ID014, date: 11/5/2022, 9:15am-10:15am PST
Oral Platform, date: 11/05/2022, 1:30pm-1:45pm PST
PCR-based Genotyping: Better, Faster and Cheaper than Whole Genome Sequencing for Known Viral Strain Identification
Poster # ID024, date: 11/04/2022, 9:15am-10:15am PST
Expanded PCR panel testing for Identification of Respiratory Pathogens and Coinfections in Influenza-like Illness
Poster # ID051, date: 11/05/2022, 9:15am-10:15am PST
Balancing Act in the Face of Variants: Testing Strategies
Poster # ID014, date: 11/04/2022, 9:15am-10:15am PST
Validation of Applied Biosystems HIV-1 Genotyping Kit with Integrase (Thermo Fisher Scientific) performed on the ABI 3500xL Genetic Analyzer platform
Poster # ID059, date: 11/05/2022, 9:15am-10:15am PST
Development of Monkeypox virus molecular control as reference material for molecular diagnostic tests
Poster # ID067, date: 11/05/2022
Development of a Multiplex RT-qPCR Assay for the Simultaneous Detection and Differentiation of Human Adenovirus, Metapneumovirus, Parainfluenza Virus and Rhinovirus/Enterovirus
Poster # ID057, date: 11/05/2022, 9:15am-10:15am PST
Development and Performance Evaluation of a Multiplex Real-Time PCR Panel for the Qualitative Detection and Differentiation of Enteric Bacterial Pathogens
Poster # ID011, date: 11/05/2022, 9:15am-10:15am PST
Precision Genotyping for EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Using a Multiplexed Digital PCR Test
Poster # ST07
Development of New Multianalyte NGS controls with microsatellite instability, tumor mutation burden and loss of heterozygosity variants
Poster # ST073, date: 11/05/2022
Development of AcroMetrix Multi-analyte cfTNA (cell free total nucleic acid) Human Plasma Controls
Poster # ST070, date: 11/05/2022
Multifaceted Research Application of Comprehensive Genomic Profiling for Detection of Cancer Variants, Gene Fusions, and Complex Oncology Endpoints
Poster # ST017, date: 11/05/2022, 9:15am - 10:15am PT
Comprehensive profiling of copy number changes to assess genomic instability
Poster # ST059, date: 11/05/2022, 9:15am - 10:15am PT
NYSDOH Initial Validation of the Oncomine™ Precision Assay for Use in Clinical Studies
Poster # ST021, date: 11/05/2022, 9:15am - 10:15am PT
Expanded International Scale (IS) Value Assignments to our BCR-ABL1 Panel and Development of Daily Controls Traceable to WHO International Standards
Poster # H031, date: 11/05/2022
Efficient Biorepository Development using Oncomine Precision Assay and the Genexus Integrated NGS Platform
Poster # I017, date: 11/05/2022, 9:15am - 10:15am PT
Automated Mutation Impact Analysis Tool for Real-Time Tracking of SARS-CoV-2 Variant Impact on COVID Diagnostic Assays
Poster # I013, date: 11/05/2022, 9:15am-10:15am PST
Labor Cost Comparison between the Thermo Fisher Scientific Genexus Integrated Sequencer and the Illumina MiSeq
Poster # G049, date: 11/05/2022, 9:15am - 10:15am PT
Precision Genotyping for EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Using Multiplexed Digital PCR on cell-free DNA
Poster # G052, date: 11/04/2022, 9:15am - 10:15am PT
For Research Use Only. Not for use in diagnostic procedures.